The global TB diagnostics market was valued at USD 1.48 billion in 2025 and is projected to grow from USD 1.56 billion in 2026 to USD 2.41 billion by 2034, registering a CAGR of 5.56% during the forecast period (2026–2034). The market is expanding steadily due to the rising global burden of tuberculosis, increasing government initiatives for TB control, growing adoption of rapid molecular diagnostic technologies, and continuous investments in public healthcare infrastructure. Technological advancements in nucleic acid amplification tests (NAATs), point-of-care diagnostics, and automated laboratory systems are further driving market growth.

Key Highlights

• The global TB diagnostics market was valued at USD 1.48 billion in 2025.
• The market is projected to reach USD 2.41 billion by 2034.
• The market is expected to grow at a CAGR of 5.56% during the forecast period (2026–2034).
• North America is the largest regional market.
• Asia-Pacific is the fastest-growing regional market.
• By Test Type, the Molecular Diagnostic Tests segment holds the largest market share.
• By End User, the Hospitals and Diagnostic Laboratories segment dominates the market.
• By Diagnostic Method, the Rapid Molecular Testing segment is the fastest-growing segment.

Market Dynamics

Market Driver

Increasing Global Burden of Tuberculosis and Advancements in Diagnostic Technologies

Tuberculosis remains one of the world's leading infectious diseases, creating sustained demand for accurate, rapid, and accessible diagnostic solutions. Governments, global health organizations, and non-governmental organizations continue to strengthen TB surveillance, screening programs, and early diagnosis initiatives to reduce disease transmission and improve treatment outcomes. Rising awareness regarding early TB detection is significantly boosting demand for advanced diagnostic technologies.

Furthermore, technological innovations such as cartridge-based molecular assays, automated nucleic acid amplification tests, digital imaging systems, and AI-assisted diagnostic platforms have considerably improved diagnostic accuracy while reducing turnaround time. These developments are supporting widespread adoption across hospitals, diagnostic laboratories, and public health programs.

Market Restraint

High Cost of Advanced Diagnostic Systems and Limited Healthcare Access

Despite significant technological advancements, advanced TB diagnostic platforms often involve substantial equipment costs, maintenance requirements, and specialized laboratory infrastructure. These financial constraints may limit adoption, particularly in low- and middle-income countries where tuberculosis prevalence remains high.

In addition, inadequate healthcare infrastructure, shortages of trained laboratory professionals, and limited access to diagnostic services in remote regions continue to hinder early disease detection. Regulatory challenges and reimbursement limitations may also slow market expansion in certain countries.

Market Opportunity

Expansion of Point-of-Care Testing and Government TB Elimination Programs

The growing emphasis on decentralized healthcare and rapid disease diagnosis is creating significant opportunities for point-of-care TB diagnostic solutions. Portable molecular testing platforms, digital health technologies, and AI-enabled diagnostic tools are improving access to tuberculosis screening in resource-limited settings and rural healthcare facilities.

Moreover, increasing investments from governments and international organizations in national TB elimination programs, coupled with expanding public-private partnerships, are expected to accelerate the adoption of innovative diagnostic technologies. Continuous research into next-generation biomarkers, digital diagnostics, and automated laboratory workflows will further create long-term growth opportunities throughout the forecast period.

Top Market Players

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Danaher Corporation
• Becton, Dickinson and Company (BD)
• bioMérieux SA
• Hologic, Inc.
• QIAGEN N.V.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Cepheid
• Fujifilm Holdings Corporation
• Sekisui Diagnostics
• SD Biosensor, Inc.
• Sysmex Corporation
• Revvity, Inc.

Market Segmentation

By Test Type

• Molecular Diagnostic Tests
• Smear Microscopy
• Culture-Based Tests
• Radiographic Tests
• Tuberculin Skin Test (TST)
• Interferon Gamma Release Assays (IGRAs)

By End User

• Hospitals
• Diagnostic Laboratories
• Academic & Research Institutes
• Others

By Region

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia-Pacific

Latin America

• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

Unlock Full Report Insights and Strategic Analysis: https://straitsresearch.com/report/tb-diagnostics-market

Gain access to comprehensive market intelligence featuring detailed market forecasts, competitive benchmarking, company profiles, regional analysis, technological innovations, regulatory landscape, investment opportunities, pipeline developments, and strategic recommendations to support informed business decisions and long-term growth.

About Us

Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.

Contact Us

Email: sales@straitsresearch.com

Tel:

• +1 646 905 0080 (U.S.)
• +44 203 695 0070 (U.K.)